ProQinase

Founded: 2001 • Age: 25 yrs Acquired By Reaction Biology
Contract research company for cancer drug discovery

About ProQinase

ProQinase is a company founded in 2001 was acquired by Reaction Biology in February 2019.. ProQinase operates in a competitive market with competitors including Orakl Oncology, Oncodesign, LumaBridge, Lytica Therapeutics and Orange Grove Bio LLC, among others.

  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Healthcare Services & Infrastructure
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Latest Funding Round
  • Investors
  • Employee Count
    Employee Count
  • Acquired by
    Reaction Biology

    (Feb 04, 2019)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of ProQinase

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in ProQinase

ProQinase has secured backing from 1 investor. Prominent investors backing the company include Reaction Biology. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Investor Description Founded Year Domain Location
In vitro enzyme activity assays, secializing in kinase & epigenetic HTS and profiling
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by ProQinase

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - ProQinase

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Proqinase Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of ProQinase

ProQinase operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Orakl Oncology, Oncodesign, LumaBridge, Lytica Therapeutics and Orange Grove Bio LLC, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Orakl Oncology is a precision oncology start-up that enables the emergence of rare oncology by connecting patient tumors to the world's 3rd best cancer center.
domain founded_year HQ Location
Preclinical assessment services for anti-cancer therapies are provided.
domain founded_year HQ Location
Provider of oncology clinical research, regulatory affairs, and data management services
domain founded_year HQ Location
Therapeutic drugs are developed for medical applications.
domain founded_year HQ Location
Provider of preclinical development services
domain founded_year HQ Location
Creates innovative platforms for anti-cancer drug development.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Proqinase

Frequently Asked Questions about ProQinase

When was ProQinase founded?

ProQinase was founded in 2001.

Who is the current CEO of ProQinase?

Roland Huber is the current CEO of ProQinase.

What does ProQinase do?

ProQinase is a leading contract research company for cancer drug discovery. The company has scientific experience in cancer research with a focus on protein kinases and tumor angiogenesis. Hits derived from biochemical kinase assays can be further characterized at ProQinase in cell-based, target-specific phosphorylation assays and in various functional cell-based assays like migration assays, proliferation assays, soft agar assays, and angiogenesis assays. ProQinases portfolio of preclinical services is completed by in vivo testing services including subcutaneous tumor models (xenograft tumor models), orthotopic tumor models with in vivo and ex vivo bioluminescence analysis and a unique in vivo angiogenesis assay. In addition, ProQinase provides custom-tailored solutions of preclinical services as support for cancer drug discovery projects.

Who are the top competitors of ProQinase?

ProQinase's top competitors include Oncodesign, Orakl Oncology and Lytica Therapeutics.

Who are ProQinase's investors?

ProQinase has 1 investor. Key investors include Reaction Biology.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available